CB-CAP Profiling for Pre-Lupus Diagnostic Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Systemic Lupus Erythematosus (Lupus) are inadequate, leading to underdiagnosis or overdiagnosis, delayed diagnosis, and increased morbidity and mortality, due to non-specific symptoms and lack of reliable biomarkers for identifying patients at risk of developing the disease.
Innovation Solution
A method and system utilizing cell-bound complement activation products (CB-CAPs) to classify patients as 'pre-Lupus' by analyzing blood samples for elevated levels of CB-CAPs, such as E-C4d, E-C3d, R-C4d, and others, compared to control levels, to determine the probability of Lupus development, enabling early detection and intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (blood tests and clinical criteria) are used for Lupus diagnosis, then the diagnostic process can be performed with existing tools, but the diagnosis lacks sufficient sensitivity and specificity leading to underdiagnosis or overdiagnosis
Solution Approach 1:
The patent changes the diagnostic parameters from general blood tests and clinical criteria to specific cell-bound complement activation products (CB-CAPs) such as C4d, C3d, and iC3b bound to specific cell types. This parameter change enables more precise measurement of complement activation status, directly improving diagnostic precision while maintaining reliability through standardized flow cytometry protocols
Solution Approach 2:
The patent replaces the mechanical/clinical assessment system (physician evaluation of symptoms and standard blood tests) with a biochemical detection system that measures specific complement activation products on cell surfaces. This substitution provides more objective and reliable diagnostic data, reducing subjectivity in diagnosis while improving precision through quantitative measurement of CB-CAP levels
2Measurement precision
If multiple blood tests and clinical evaluations are performed to improve diagnosis accuracy, then diagnostic precision may improve, but the time required for diagnosis increases significantly
Solution Approach 1:
The patent merges multiple diagnostic functions into a single flow cytometry assay that simultaneously evaluates multiple CB-CAP parameters (C4d, C3d, iC3b) on various cell types. This consolidation maintains high diagnostic precision by assessing complement activation comprehensively while reducing the time required compared to performing separate tests for each parameter
Solution Approach 2:
The patent performs preliminary assessment of complement activation status through CB-CAP measurement, which can identify patients at risk for Lupus before full clinical criteria are met. This preliminary action enables earlier intervention and reduces the overall time to diagnosis by detecting disease processes at an earlier stage rather than waiting for multiple clinical manifestations to develop
3Ease of operation
If standard blood tests are used for Lupus screening, then the screening process is simple and cost-effective, but the tests lack the sensitivity to detect early disease manifestations
Solution Approach 1:
The patent uses cell-bound complement activation products as intermediary markers that bridge the gap between simple screening and definitive diagnosis. These CB-CAPs serve as measurable intermediaries that reflect underlying complement activation processes in Lupus, enabling sensitive detection of early disease manifestations while maintaining operational simplicity through flow cytometry technology
Solution Approach 2:
The patent changes the screening parameters from general immune markers to specific complement activation products bound to cells. This parameter change dramatically improves detection sensitivity for early Lupus manifestations while maintaining ease of operation through standardized flow cytometry protocols that can be implemented in routine clinical laboratories
4Reliability
If diagnostic criteria are applied strictly to avoid overdiagnosis, then false positives are reduced, but patients with early or atypical Lupus presentations are missed
Solution Approach 1:
The patent performs preliminary detection of complement activation through CB-CAP measurement before applying full diagnostic criteria. This preliminary action identifies patients with early disease processes who may not yet meet strict diagnostic criteria, allowing for further evaluation and intervention before progression to overt Lupus, thus improving early disease detection without compromising diagnosis accuracy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Cell-bound complement activation product (CB-CAP) profiling and scoring serve as diagnostic biomarkers for patients to determine whether a patient who has not met at least four American College of Rheumatology (or similar e.g. SLICC) criteria for a definite Lupus diagnosis should be classified as exhibiting a pre-existing condition that this document refers to as pre-Lupus.